Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A group of autoimmune conditions characterized by inflammation of the limbic system and other parts of the brain.The cardinal sign of limbic encephalitis is a severe impairment of short-term memory; however,symptoms may also include confusion, psychiatric symptoms, and seizures.The symptomstypically develop over a few weeks or months, but they may evolve over a few days. Limbic encephalitis is often associated with an underlying neoplasm (paraneoplastic limbic encephalitis); however some cases never have a neoplasm identified (non-paraneoplastic limbic encephalitis). Delayed diagnosis is common, but improvements are being made to assist in early detection. Various tests including imaging studies (MRI, PET) laboratory tests (CSF analysis), and tests that measure the electrical activity of the brain (EEG) may be utilized to confirm a diagnosis. Treatment includes removal of the neoplasm (if identified) and immunotherapy.
Biomarker and diagnostic research for limbic encephalitis has been reported in the published literature.
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
223 publications have been identified in PubMed for limbic encephalitis. Research spans Case Report / Case Series (53%), Review / Meta-Analysis (17%), and Clinical Trial Publication (8%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 118 | 53% |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 6:01 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries | 38 | 17% |
Clinical study results | 18 | 8% |
Laboratory research | 16 | 7% |
Disease patterns and progression | 13 | 6% |
Other research | 10 | 4% |
Testing and diagnosis research | 10 | 4% |
Demas A (2026). [PMID: 42180214](https://pubmed.ncbi.nlm.nih.gov/42180214/). *Front Neurol*. [Review / Meta-Analysis]
Mazzeo A (2026). [PMID: 41882230](https://pubmed.ncbi.nlm.nih.gov/41882230/). *Neurol Sci*. [Other]
Chen J (2026). [PMID: 42099514](https://pubmed.ncbi.nlm.nih.gov/42099514/). *Front Pediatr*. [Case Report / Case Series]
Dorneich JS (2026). [PMID: 41876947](https://pubmed.ncbi.nlm.nih.gov/41876947/). *Ann Clin Transl Neurol*. [Diagnostic / Biomarker]
Kakarala CL (2026). [PMID: 41629117](https://pubmed.ncbi.nlm.nih.gov/41629117/). *BMJ Case Rep*. [Case Report / Case Series]
Aytaç A (2026). [PMID: 41323171](https://pubmed.ncbi.nlm.nih.gov/41323171/). *Radiol Case Rep*. [Case Report / Case Series]
Thomsen AN (2026). [PMID: 41474363](https://pubmed.ncbi.nlm.nih.gov/41474363/). *Epilepsia*. [Clinical Trial Publication]
Khalid A (2026). [PMID: 41769134](https://pubmed.ncbi.nlm.nih.gov/41769134/). *Sage Open Pediatr*. [Case Report / Case Series]
Majoul MS (2026). [PMID: 41664124](https://pubmed.ncbi.nlm.nih.gov/41664124/). *Journal of medical case reports*. [Clinical Trial Publication]
Sumiyoshi S (2026). [PMID: 41778237](https://pubmed.ncbi.nlm.nih.gov/41778237/). *Cancer diagnosis & prognosis*. [Case Report / Case Series]